MARKET

BTAI

BTAI

Bioxcel Therapeutics Inc
NASDAQ
1.020
-0.040
-3.77%
Pre Market: 1.030 +0.01 +0.98% 04:08 04/14 EDT
OPEN
1.040
PREV CLOSE
1.060
HIGH
1.080
LOW
1.010
VOLUME
165
TURNOVER
0
52 WEEK HIGH
8.08
52 WEEK LOW
1.010
MARKET CAP
27.62M
P/E (TTM)
-0.1782
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BTAI last week (0406-0410)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Bioxcel Therapeutics (BTAI)
TipRanks · 4d ago
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PR Newswire · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
Reuters · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Reuters · 5d ago
BioXcel Therapeutics Begins Enrollment In DoW-Funded Study Of BXCL501 For Acute Stress Reactions
NASDAQ · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana
Reuters · 5d ago
BUZZ-BioXcel rises as trial starts for its stress disorder drug in trauma victims
Reuters · 5d ago
More
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Webull offers BioXcel Therapeutics Inc stock information, including NASDAQ: BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.